Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 9:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 4,117 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Experimental 2 Clear all

Conditions: Hot Flashes
Interventions: Hypnosis, Structured Attention; Behavioral · Other
Lead sponsor: Baylor University; Other
Eligibility: 40 Years and older · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Waco, Texas

Conditions: Critically Ill
Interventions: Intervention Group; Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Ortho-Cyclen, Dolutegravir, Placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Dry Eye
Interventions: SDP-4 Ophthalmic Solution (0.1%), SDP-4 Ophthalmic Solution (1.0%), SDP-4 Ophthalmic Solution (3.0%), Vehicle; Drug
Lead sponsor: Silk Technologies, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 26
States / cities: Azusa, California • Garden Grove, California • Mission Hills, California + 22 more

Conditions: Clostridium Difficile Diarrhea
Interventions: PBCLN-003, Placebo; Drug
Lead sponsor: Prolacta Bioscience; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Idaho Falls, Idaho

Conditions: Neoplasms
Interventions: PF-00299804; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 8
States / cities: Los Angeles, California • Santa Monica, California • Aurora, Colorado + 1 more

Conditions: Chronic Limb Ischemia
Interventions: Temsirolimus, Saline; Drug
Lead sponsor: Mercator MedSystems, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 8
States / cities: Little Rock, Arkansas • Orange, California • Denver, Colorado + 5 more

Conditions: Merkel Cell Carcinoma
Interventions: Pembrolizumab, Lutetium Lu 177 dotatate; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Duarte, California • Iowa City, Iowa • New York, New York + 1 more

Conditions: Pain Management, Peripheral Neuropathic Pain
Interventions: Cold Pressor Task - Upper Limb, Algometry Pain Tests in the Upper Limb, Algometry Pain Tests in the Lower Limb; Device
Lead sponsor: Evan (Huiliang) Wang; Other
Eligibility: 20 Years to 40 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Advanced or Metastatic Breast Cancer
Interventions: PF-07220060 CDK4 inhibitor, Fulvestrant, Everolimus, Exemestane; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 9
States / cities: Irvine, California • Los Angeles, California • Newport Beach, California + 3 more

Conditions: Lupus Nephritis (LN)
Interventions: Vonsetamig, Odronextamab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: San Francisco, California • Gainesville, Florida • Rochester, Minnesota + 1 more

Conditions: Advanced Solid Tumor
Interventions: OMTX705, Pembrolizumab, Tislelizumab (BGB-A317); Drug
Lead sponsor: Oncomatryx Biopharma S.L.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alcohol Abuse
Interventions: MI/Family Check-up, MI only; Behavioral
Lead sponsor: Brown University; Other
Eligibility: 13 Years to 17 Years
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Critical Limb Ischemia
Interventions: Ticagrelor; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 80 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Major Depressive Disorder
Interventions: Valganciclovir, Placebo; Drug
Lead sponsor: Laureate Institute for Brain Research, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Acne
Interventions: IDP-121 Lotion, IDP-121 Vehicle Lotion; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 9 Years and older
Enrollment: 820 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 39
States / cities: Guntersville, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 34 more

Conditions: Healthy
Interventions: Ramipril10 mg Capsules, single dose, Atlace® 10 mg capsules, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Inflammation, C-reactive Protein, Exercise Capacity
Interventions: Active Fruit Juice Intervention, Control Fruit Juice Intervention; Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Sclerosing Cholangitis
Interventions: Volixibat, Placebo; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 34
States / cities: Coronado, California • Los Angeles, California • Sacramento, California + 26 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSVPreF3(120 μg), Flu Quadrivalent influenza vaccine (15 μg HA), Placebo; Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 1,586 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: West Palm Beach, Florida • Stockbridge, Georgia • Peoria, Illinois + 2 more

Conditions: Solid Tumors
Interventions: LY573636, Pemetrexed; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Surgery, Health Knowledge, Attitudes, Practice, Colorectal Disorders
Interventions: Educational intervention (VISACT); Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 1,050 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Lymphoma, Non-Hodgkin, Multiple Myeloma
Interventions: G-CSF and plerixafor; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 5
States / cities: Duarte, California • Beech Grove, Indiana • Rochester, New York + 2 more

Conditions: Rheumatoid Arthritis
Interventions: PF-06650833, Placebo, Tofacitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 15
States / cities: Tuscaloosa, Alabama • Tucson, Arizona • Clearwater, Florida + 9 more

Search by objective public record fields.

A Mobile App for Hot Flashes and Sleep Disturbances

Managing Acute Pain in Critically Ill Non-communicative Palliative Care Patients

Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol

Study to Evaluate the Safety and Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED)

A Study of Safety of PBCLN-003 Following Antibiotic Therapy in Subjects With C.Difficile-associated Diarrhea

Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors

Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO)

Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer

Wearable Focused Ultrasound Stimulation for Peripheral Nerve Pain Management

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.

Brief Intervention for Families of Teens Treated in the Emergency Department for an Alcohol-Related Event

Switch to Ticagrelor in Critical Limb Ischemia Anti-platelet Study

ANTIVIRAL TREATMENT OF CYTOMEGALOVIRUS IN DEPRESSION

Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Participants With Acne Vulgaris

A Relative Bioavailability Study of Ramipril 10 mg Capsules Administered Orally as a Sprinkle on Applesauce

What is the Effect of Increased Consumption of Fruit Juice on Exercise Capacity and Inflammatory Biomarkers?

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.

A Phase 1 Study in Patients With Solid Tumors

Adapting Enhanced Recovery Programs for Low Health Literacy Patients

Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients

Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate